PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology.
PreciseDx has raised $11.2M in total funding. The most recent round was Series B. The last funding was announced in June 2025.
PreciseDx's investors include Agilent Technologies, Quest Diagnostics, LabCorp, Mount Sinai Health System, Eventide.
PreciseDx is headquartered in New York, United States.
PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology.
PreciseDx is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"PreciseDx — Funding & Investors." VCBacked, June 5, 2025, https://www.vcbacked.co/company/precisedx. Accessed August 23, 2026.
VCBacked. (2025). PreciseDx — Funding & Investors. Retrieved August 23, 2026, from https://www.vcbacked.co/company/precisedx
{{cite web |title=PreciseDx — Funding & Investors |url=https://www.vcbacked.co/company/precisedx |website=VCBacked |access-date=August 23, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated